莫西沙星与左氧氟沙星治疗copd加重期疗效与安全性的meta分析.doc
约8页DOC格式手机打开展开
莫西沙星与左氧氟沙星治疗copd加重期疗效与安全性的meta分析,莫西沙星与左氧氟沙星治疗copd加重期疗效与安全性的meta分析摘要：通过系统评价莫西沙星（moxifloxacin）与左氧氟沙星（levofloxacin）。比较二者在治疗慢性阻塞性肺疾病（copd）加重期的临床疗效和安全性。为临床应用提供更优化的方案。计算机检索cnki、wanfang data、中国生物医学文献数...
内容介绍
此文档由会员 一切如愿8 发布
莫西沙星与左氧氟沙星治疗COPD加重期疗效与安全性的Meta分析
摘要：通过系统评价莫西沙星（moxifloxacin）与左氧氟沙星（levofloxacin）。比较二者在治疗慢性阻塞性肺疾病（COPD）加重期的临床疗效和安全性。为临床应用提供更优化的方案。计算机检索CNKI、WanFang Data、中国生物医学文献数据库。检索时间为2000年至2012年。收集比较moxifloxacin与levofloxacin治疗COPD加重期的RCT。剔除不符合要求的文献后，使用RevMan5.0软件进行Meta分析。共纳入7个RCT，共计409例COPD患者。Meta分析结果显示：在总有效率方面，莫西沙星高于左氧氟沙星[OR=2.79，95%Cl（1.56,5.01），P=0.0006]；在细菌清除率方面，moxifloxacin也显著高于levofloxacin [OR=2.27，95%Cl（1.23,4.19），P=0.009]。409例患者中，moxifloxacin的不良反应共发生了13例，而levofloxacin的发生了22例。moxifloxacin的总有效率与细菌清除率均显著高于levofloxacin。而且moxifloxacin的不良反应发生数较少。因此可以考虑釆用莫西沙星来代替左氧氟沙星用于COPD加重期的治疗。
关键词：莫西沙星；左氧氟沙星；COPD；Meta分析；
Meta-analysis of moxifloxacin and levofloxacin in the treatment of COPD exacerbations of efficacy and safety
Abstract:To assess the clinically effectiveness and safety of moxifloxacin versus levofloxacin for the treatment of acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Provides a more optimal solution for clinical applications.Such databases as CNK,WanFang Data and Chinese Biomedical Literature Database were electronically searched.The search time was 2000 to 2012. After removing non-compliant literature, a meta-analysis using the software RevMan5.0, collection compared to the treatment of levofloxacin and moxifloxacin of COPD exacerbation Of RCT. Total of seven trials, a total of 409 patients with human patients with COPD.The results of meta-analysis showed that ,to efficiency ,moxifloxacin group was significantly superior to levofloxacin group [OR=2.79,95%Cl（1.56,5.01）,P=0.0006].Clearance rate of bacteria,Tmoxifloxacin was also significantly higher than levofloxacin [OR = 2.27, 95% CI (1.23,4.19), P = 0.009].A total of 409 patients, the adverse reactions of moxifloxacin group has 13 cases and the levofloxacin group has 22 cases. To improve the clearance rate of bacteria and efficiency, moxifloxacin is superior to reduce the side effects of treatment of AECOPD, to levofloxacin.Hence it is considerable to use moxifloxacin instead oflevonoxacin in the treatment of AECOPD if necessary.
Keywords: Moxifloxacin;Levofloxacin;COPD;Meta-analysis
摘要：通过系统评价莫西沙星（moxifloxacin）与左氧氟沙星（levofloxacin）。比较二者在治疗慢性阻塞性肺疾病（COPD）加重期的临床疗效和安全性。为临床应用提供更优化的方案。计算机检索CNKI、WanFang Data、中国生物医学文献数据库。检索时间为2000年至2012年。收集比较moxifloxacin与levofloxacin治疗COPD加重期的RCT。剔除不符合要求的文献后，使用RevMan5.0软件进行Meta分析。共纳入7个RCT，共计409例COPD患者。Meta分析结果显示：在总有效率方面，莫西沙星高于左氧氟沙星[OR=2.79，95%Cl（1.56,5.01），P=0.0006]；在细菌清除率方面，moxifloxacin也显著高于levofloxacin [OR=2.27，95%Cl（1.23,4.19），P=0.009]。409例患者中，moxifloxacin的不良反应共发生了13例，而levofloxacin的发生了22例。moxifloxacin的总有效率与细菌清除率均显著高于levofloxacin。而且moxifloxacin的不良反应发生数较少。因此可以考虑釆用莫西沙星来代替左氧氟沙星用于COPD加重期的治疗。
关键词：莫西沙星；左氧氟沙星；COPD；Meta分析；
Meta-analysis of moxifloxacin and levofloxacin in the treatment of COPD exacerbations of efficacy and safety
Abstract:To assess the clinically effectiveness and safety of moxifloxacin versus levofloxacin for the treatment of acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Provides a more optimal solution for clinical applications.Such databases as CNK,WanFang Data and Chinese Biomedical Literature Database were electronically searched.The search time was 2000 to 2012. After removing non-compliant literature, a meta-analysis using the software RevMan5.0, collection compared to the treatment of levofloxacin and moxifloxacin of COPD exacerbation Of RCT. Total of seven trials, a total of 409 patients with human patients with COPD.The results of meta-analysis showed that ,to efficiency ,moxifloxacin group was significantly superior to levofloxacin group [OR=2.79,95%Cl（1.56,5.01）,P=0.0006].Clearance rate of bacteria,Tmoxifloxacin was also significantly higher than levofloxacin [OR = 2.27, 95% CI (1.23,4.19), P = 0.009].A total of 409 patients, the adverse reactions of moxifloxacin group has 13 cases and the levofloxacin group has 22 cases. To improve the clearance rate of bacteria and efficiency, moxifloxacin is superior to reduce the side effects of treatment of AECOPD, to levofloxacin.Hence it is considerable to use moxifloxacin instead oflevonoxacin in the treatment of AECOPD if necessary.
Keywords: Moxifloxacin;Levofloxacin;COPD;Meta-analysis
